CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin
Study to evaluate efficacy and safety of Berubicin in the treatment of adult recurrent Glioblastoma Multiforme (GBM), one of the most aggressive types of brain cancer
Interim analysis of trial when 50% of planned subjects reach 6 months in study
Sublicensee, WPD Pharmaceuticals to initiate a Phase 2 multicenter clinical trial in Poland of Berubicin in GBM in the second half of 2021; Interim analysis of the first 18 adult patients expected in first half of 2022
News provided by
Share this article
(NASDAQ: CNSP) ( CNS or the Company ), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM.
Virginia teacher says critical race theory has damaged community as frustrated parents demand changes
foxnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foxnews.com Daily Mail and Mail on Sunday newspapers.
Cops investigate Facebook group that named parents against critical race theory
dailymail.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailymail.co.uk Daily Mail and Mail on Sunday newspapers.